Pantheon Vision
Pantheon Vision is a Baltimore-based pre-clinical ophthalmic medical device company developing bioengineered corneal implants to treat corneal blindness, reducing reliance on scarce donor tissue for patients globally, particularly in underserved low-and-middle-income markets.
- Company typePrivate
- Founded2021
- HeadquartersBaltimore, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pantheon Vision does
Pantheon Vision is a pre-clinical ophthalmic medical device company developing bioengineered corneal implants to treat corneal blindness. Founded in 2021 and headquartered in Baltimore, Maryland, the company is building a single core product: a bioengineered implant designed to replace or reduce dependence on donated corneal tissue for sight-restoring surgery. The company targets the 12.7 million-plus patients globally suffering from corneal blindness, with an explicit focus on low-and-middle-income countries where donor tissue scarcity and lack of trained surgeons limit access to transplantation. Currently pre-revenue and pre-clinical, Pantheon Vision plans to engage the FDA for global product development, with future revenue expected from medical device sales routed through healthcare providers and eye care centers.
The underlying technology is described as bioengineered corneal implants, a novel architectural approach aimed at addressing graft acceptance, vision restoration longevity, and donor-tissue scarcity. No pricing model exists yet, and no commercial distribution channels have been established. The company maintains a minimal digital footprint (LinkedIn, Facebook, X/Twitter) and an email newsletter signup, consistent with pre-commercial awareness-building rather than demand generation. To date, the company has disclosed a single institutional capital partner — KeraLink International — which has provided $2.5 million in seed funding (November 2023) and an additional $1.8 million (April 2024), totaling $4.3 million in disclosed funding. No patents, management team bios, certifications, or named customers are publicly disclosed in available sources.
Pantheon Vision firmographics
Firmographics- Name
- Pantheon Vision
- Legal name
- Pantheon Vision
- Website
- https://pantheonvision.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Pantheon Vision is a Baltimore-based pre-clinical ophthalmic medical device company developing bioengineered corneal implants to treat corneal blindness, reducing reliance on scarce donor tissue for patients globally, particularly in underserved low-and-middle-income markets.
- Ownership category
- akta.pro rank
Pantheon Vision industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)
- akta.pro secondary industry
- Ophthalmic Regeneration (cornea/retina) (HLAAAGAK)
Keywords
Where Pantheon Vision is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pantheon Vision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Medical Device Sales (Future): Pre-clinical stage company developing bioengineered corneal implants. No commercial revenue currently. Future revenue expected from sale of medical devices for corneal blindness treatment.
Marketing channels2 records
Pantheon Vision product offering
Product offeringCore offering
Pantheon Vision develops a bioengineered corneal implant designed to prevent and treat corneal blindness without reliance on donated corneal tissue. The implant is intended to address corneal opacity caused by infection, disease, or trauma and is being positioned as a scalable alternative to traditional donor-tissue corneal transplantation. The company is pre-clinical, has no commercial revenue, and is planning FDA engagement to support global product development.
Product overview
Pantheon Vision is an early research-stage medical device company developing a single core product: a bioengineered corneal implant. The company is in pre-clinical stage and plans to engage the FDA for global product development. Their bioengineered solution targets corneal blindness—one of the leading causes of avoidable blindness globally—aiming to restore vision while reducing dependence on scarce donor tissue and addressing treatment access limitations worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- Bioengineered Corneal Implant A bioengineered implant designed to prevent and treat corneal blindness by reducing reliance on donated corneal tissue. Indicated for corneal opacity caused by infection, disease, or trauma, providing an alternative to traditional donor-tissue transplantation for ophthalmology hospitals, eye-care centers, and transplant programs serving patients with corneal blindness.
Companies that use Pantheon Vision
Customer profileSegments1 record
Ideal customer profiles1 record
Pantheon Vision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Pantheon Vision partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights3 records
Pantheon Vision competitors and assessment
Company assessmentDirect peers
- CorNeat Vision: Israel-based ophthalmic medical device company developing synthetic, non-decellularized corneal implants (CorNeat KPro) to treat corneal blindness without donor tissue. Closest direct competitor to Pantheon Vision's bioengineered approach, targeting the same unmet need with a parallel technology pathway.
- Aurion Biotech: Clinical-stage cell therapy company developing allogeneic corneal endothelial cell therapies (neltependocel) for corneal endothelial disease. Competes for the same corneal blindness patient pool with a regenerative-medicine approach directly comparable to Pantheon's bioengineered tissue strategy.
- Recornea: Italy-based medical device company developing bioengineered corneal implants (EndoGlide and regenerative therapies) for corneal blindness. One of the most direct comparables in terms of implant form factor and bioengineering approach.
Emerging players
- Cellusion Inc. Japan-based regenerative medicine startup developing corneal endothelial cell therapies derived from iPSCs to treat bullous keratopathy and corneal blindness. Competes on the same regenerative axis as Pantheon Vision but uses a cell-based rather than implant-based approach.
- Eyevance Pharmaceuticals: Ophthalmic-focused specialty pharma company developing therapeutics for ocular surface and anterior segment conditions. Comparable as a small ophthalmic-focused commercial-stage company navigating ophthalmic market access.
Broad incumbents
- TissueTech / BioTissue: Established regenerative ophthalmic company commercializing amniotic membrane and placental tissue products (AmnioGuard, Prokera) for ocular surface reconstruction. Larger, revenue-generating incumbent operating in adjacent ocular surface and corneal indications.
- Alcon: Global ophthalmic medical device and pharmaceutical leader with deep presence in cataract surgery, corneal transplant instrumentation, and ocular surface products. Relevant as a potential strategic acquirer or partner and a benchmark for ophthalmic medtech commercial scale.
- Johnson & Johnson Vision: Diversified ophthalmic medtech division of J&J covering cataract, refractive surgery, and corneal health products. Comparable as a broad incumbent that could absorb bioengineered corneal innovation through acquisition or licensing.
- Bausch + Lomb: Global ophthalmic medical device and pharmaceutical company with an established surgical portfolio including corneal transplant instrumentation and eye banking partnerships. Broad incumbent benchmark in corneal care.
Regional players
- KeraMed (KeraPro): European corneal graft and lamellar tissue processor serving corneal surgeons globally with processed donor tissue products. Relevant adjacent comparable highlighting the existing donor-tissue paradigm Pantheon seeks to disrupt.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key highlights6 records
Customer concentration
Pantheon Vision social profiles
Digital presencePantheon Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pantheon Vision leadership team
Management profileNumber of profiles
Pantheon Vision funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pantheon Vision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pantheon Vision
What does Pantheon Vision do?
Pantheon Vision develops a bioengineered corneal implant designed to prevent and treat corneal blindness without reliance on donated corneal tissue. The implant is intended to address corneal opacity caused by infection, disease, or trauma and is being positioned as a scalable alternative to traditional donor-tissue corneal transplantation. The company is pre-clinical, has no commercial revenue, and is planning FDA engagement to support global product development.
Is Pantheon Vision a public or private company?
Pantheon Vision is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pantheon Vision founded?
Pantheon Vision was founded in 2021. It employs 1 to 10 people.
Where is Pantheon Vision based?
Pantheon Vision is headquartered in Baltimore, United States, in the North America region.
How does Pantheon Vision make money?
One revenue line is on record: medical Device Sales (Future).
Who are Pantheon Vision's main competitors?
Direct peers on record are CorNeat Vision, Aurion Biotech and Recornea. Emerging players are Cellusion Inc. and Eyevance Pharmaceuticals. Broad incumbents are TissueTech / BioTissue, Alcon, Johnson & Johnson Vision and Bausch + Lomb. KeraMed (KeraPro) is listed as a regional player.
Does Pantheon Vision have an API?
No public API is recorded for Pantheon Vision.
What industry is Pantheon Vision in?
Pantheon Vision's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of HLAAAGAK, Ophthalmic Regeneration (cornea/retina). Its NAICS code is 339115 and its SIC code is 3841.